Diagnostic test utilization: balancing clinical value and cost

A large claims analysis found that 23.8% of tested individuals underwent excessive testing across four common outpatient laboratory categories, generating more than $350 million in conservative direct excess costs in the 2019 claims baseline.

The operational response cannot be a blunt reduction in test volume. That approach damages access, delays diagnosis, and creates a different form of waste: underutilization. The objective is controlled utilization. Every test should have a defensible clinical purpose, an appropriate timing pattern, a reliable specimen pathway, and a result that can be acted upon.

For laboratory directors and hospital administrators, this requires more than a physician education campaign. It requires a management system that connects order entry, clinical decision support, reflex rules, specimen control, payer policy, result follow-up, and financial reporting.

The economic and clinical impact of diagnostic overutilization

Laboratory utilization has a measurable cost at every stage of the diagnostic service line. The obvious expense is the assay itself. The less visible cost sits in the surrounding workflow:

• Phlebotomy and specimen collection time.
• Accessioning and accession correction.
• Reagent and consumable consumption.
• Analyzer capacity and maintenance.
• Medical technologist review.
• Pathologist interpretation.
• Result communication and follow-up.
• Repeat testing caused by unclear or conflicting results.
• Payer disputes and retrospective medical-necessity review.
• Storage, transport, and disposal of specimens.

In molecular diagnostics and precision medicine, the financial exposure is substantially higher. Advanced genomic panels for cancer diagnosis can cost anywhere from $500 to $15,000 per test. A poorly governed order is therefore not equivalent to an unnecessary basic chemistry panel. It can consume a significant portion of a patient’s diagnostic budget before the clinical team has established whether the result will change management.

The financial case for laboratory diagnostic test utilization management strategies is strong. But cost reduction is not the operating definition of stewardship. A test is not wasteful merely because it is expensive, and a low-cost test is not automatically appropriate. The relevant question is whether the test is correctly selected, correctly performed, correctly interpreted, and connected to a clinical decision.

A useful utilization program tracks both excess and omission. The five principal drivers of inappropriate laboratory testing are:

1. Clinician test selection error. The requested assay does not match the clinical question, or a broader panel is ordered when a narrower test would provide the necessary information.

2. Incorrect laboratory testing procedure. The specimen, timing, preparation, transport, or processing does not support a valid result.

3. Misinterpretation of results. A result is read outside its clinical context or treated as definitive when it is only one component of the diagnostic workup.

4. Omission of clinically indicated testing. The needed test is not ordered, creating underutilization and potential diagnostic delay.

5. Failure to follow up on test results. The laboratory produces a result, but no accountable clinician acts on it.

This framework matters because each failure requires a different intervention. A formulary may address selection error. It will not solve a specimen transport problem. A reflex algorithm may prevent redundant testing. It will not ensure that an abnormal molecular result reaches the treating team.

The laboratory does not control utilization by performing fewer tests. It controls utilization by making the right test the easiest test to order, process, interpret, and act upon.

Drivers of inappropriate testing: where the workflow breaks

The standard utilization discussion often stops at physician ordering behavior. That is too narrow for a modern pathology or molecular diagnostics operation. Test utilization is a workflow outcome. The final order reflects the interaction between clinical uncertainty, electronic configuration, local practice, payer rules, and laboratory operations.

Selection errors begin before the order reaches the laboratory

A clinician may select an attractive but excessive test because the electronic health record presents a long list of similarly named assays. This is particularly common in molecular pathology, where panels, add-on studies, single-gene assays, fusion testing, copy-number analysis, and sequencing options may appear together without an obvious decision path.

The resulting error is not always a lack of knowledge. It may be a design failure. If the order menu does not distinguish first-line tests from escalation tests, the system effectively delegates formulary management to the busiest person in the clinical workflow.

A functional order environment should make the intended sequence visible:

• Start with the test that answers the immediate clinical question.
• Identify the specimen requirements before collection.
• Show whether a reflex pathway is available.
• Display duplicate or recently completed testing.
• State when a broader panel should be reserved for a defined indication.
• Route unusual or high-cost orders for review without creating an unmanageable administrative queue.

The objective is not to place a warning on every assay. Excessive alerts create alert fatigue and turn a compliance tool into background noise. Decision support must be selective. It should intervene where the risk of redundancy, inappropriate timing, or high-cost misuse is material.

Timing creates a large share of avoidable volume

Repeated testing is often clinically defensible in principle but inappropriate in timing. A result may be reordered before the prior result could reasonably change, before the relevant biological interval has elapsed, or while the same specimen is still available for an additional approved test.

This is where pathology test utilization metrics become operationally useful. The laboratory should identify repeat-order patterns by:

• Test code and panel family.
• Ordering department.
• Patient location.
• Time interval between orders.
• Result status at the time of reorder.
• Specimen type.
• Payer category.
• Ordering clinician or service line.
• Whether a reflex or add-on route was available.

The metric is not simply the number of repeated tests. The useful measure is the proportion of repeat orders that were clinically necessary, technically necessary, or preventable through workflow design.

A high repeat rate can indicate several different problems:

• The first result was not available at the point of care.
• The initial specimen was inadequate.
• The result was not trusted.
• The ordering team did not know the test had already been performed.
• The clinical condition changed.
• The laboratory reporting format did not make the result actionable.

Only some of these are solved by restricting orders. The rest require faster turnaround, better result display, improved preanalytical quality control, or clearer reporting.

Underutilization is a margin and quality problem as well

Underutilization is often treated as a clinical issue outside laboratory management. That is a mistake. Missed testing can lead to repeat visits, delayed treatment, avoidable referrals, and additional downstream diagnostic work. It also weakens the laboratory’s role as a clinical partner.

A stewardship program that measures only avoided tests will eventually create resistance. Clinical teams will see the program as a cost-control function rather than a diagnostic quality function. The dashboard must therefore include both sides of the utilization equation:

• Avoided duplicate orders.
• Appropriate reflex testing.
• Reduction in rejected or compromised specimens.
• Timely completion of clinically indicated testing.
• Unresolved abnormal results.
• Add-on test utilization.
• Repeat collection caused by preanalytical failure.
• Orders diverted to a more appropriate assay.
• High-cost tests approved, modified, or declined after review.

This gives leadership a more accurate view of value. The target is not the lowest possible test count. The target is the lowest avoidable operational burden consistent with safe diagnosis.

Evidence-based stewardship: CPOE, reflex algorithms, and decision support

The strongest laboratory stewardship programs do not depend on a single control. Computerized provider order entry, reflex testing, and combination strategies have achieved CDC Laboratory Medicine Best Practices evidence thresholds for managing inappropriate laboratory test overutilization.

That finding has a practical implication: laboratories should stop treating stewardship as an education-only initiative. Education is useful. It is not durable control. A clinician may agree with a utilization policy and still order the wrong test under time pressure if the electronic workflow makes the wrong option faster.

Build controls into the order pathway

Computerized provider order entry should perform several basic functions without forcing the laboratory to manually police every request:

1. Duplicate detection. Display recent equivalent or overlapping tests before a new order is finalized.

2. Indication capture. Require a concise clinical indication for selected high-cost or high-complexity assays.

3. Specimen guidance. Show required specimen type, collection conditions, and handling requirements at the point of order.

4. Reflex visibility. Explain whether the initial assay can trigger an approved reflex pathway.

5. Restriction logic. Route selected orders to a pathology, genetics, or laboratory medicine review process.

6. Result availability. Make prior relevant results visible before the new order is submitted.

7. Exception documentation. Allow a clinician to proceed when the clinical circumstance justifies deviation from the default pathway.

The exception process is essential. A system that blocks all deviations encourages workarounds, informal testing, and uncontrolled send-outs. A system that captures the reason for an exception creates data for program refinement.

Use reflex testing to reduce avoidable ordering

Reflex testing is one of the most effective tools for converting a complex sequence into a controlled laboratory pathway. The initial test establishes whether the next assay is warranted. If the defined condition is met, the laboratory performs the next step without requiring a second clinician order.

This can reduce:

• Duplicate order entry.
• Delayed escalation.
• Inconsistent test sequencing.
• Specimen recollection.
• Unnecessary broad-panel use.
• Manual review of routine, predictable pathways.

A reflex algorithm should be designed with clinical ownership. The laboratory can define analytical and operational conditions, but the relevant clinical service must confirm that the pathway reflects current diagnostic practice. Governance should include laboratory medicine, pathology, the affected specialties, nursing or collection leadership where relevant, informatics, compliance, and revenue cycle representatives.

The algorithm also requires maintenance. A reflex rule that remains in the LIS or electronic health record after the underlying assay, payer policy, specimen requirement, or clinical guideline changes becomes a compliance risk.

Integrate LIS and EHR data rather than operating separate control systems

A laboratory information system can contain the information needed to manage utilization, but only if the data are connected across the order-to-result process. Key fields should allow the organization to trace:

• The original order.
• Any modified or replaced order.
• The specimen accession.
• The testing location.
• The reflex or add-on decision.
• The final result.
• The billing code.
• The payer response.
• The follow-up status.

Without this linkage, leadership sees isolated events rather than a process. A canceled order may look like a saving even when the same test was reordered under a different code. A rejected specimen may look like a collection issue even when the ordering interface gave incorrect container guidance. A denied molecular test may be recorded as a payer problem even when the order lacked a required indication.

Data integrity is therefore part of utilization management. The organization cannot manage throughput, margin, or compliance from fragmented records.

Establish a review cadence with accountable owners

A stewardship program needs a management rhythm. Monthly review may be appropriate for high-volume routine tests. High-cost molecular and genomic panels may require more frequent exception monitoring during implementation.

The review should answer concrete questions:

• Which tests generated the greatest preventable volume?
• Which departments show persistent repeat ordering?
• Which alert produces the highest override rate?
• Which reflex rules are underused?
• Where are specimens repeatedly rejected?
• Which payer policies create avoidable rework?
• How much review capacity is consumed by low-value exceptions?
• Are reductions in volume accompanied by increased turnaround time or missed testing?

Each metric requires an owner. If a metric has no owner, it becomes a report rather than a management tool.

Managing high-cost precision medicine and genomic panels

Precision medicine magnifies the consequences of poor utilization design. A genomic panel priced between $500 and $15,000 can be clinically valuable, but its value depends on the question it is intended to answer, the adequacy of the specimen, the interpretive framework, and the availability of a treatment or diagnostic decision that can use the result.

The laboratory should manage these tests as a service line, not as isolated transactions.

Define the clinical purpose before expanding the menu

A high-cost panel should have a defined role in the diagnostic pathway. It may be used for classification, treatment selection, recurrence assessment, hereditary risk evaluation, or resolution of an unresolved diagnostic question. Those purposes are not interchangeable.

The utilization policy should distinguish:

• First-line testing.
• Confirmatory testing.
• Escalation after an non-diagnostic result.
• Testing required for a specific therapy or trial.
• Testing that requires genetic counseling or specialist review.
• Testing that may be deferred because the result is unlikely to change current management.

This is not an argument against broad testing. It is an argument for sequencing. A broad panel can be the correct first step in one clinical context and an expensive detour in another.

Control specimen adequacy before the test is launched

A failed or limited specimen is an operational loss before the sequencing run begins. Tissue quantity, tumor fraction, fixation quality, decalcification history, contamination, and DNA or RNA integrity can determine whether the assay will produce a usable result.

Preanalytical quality control should therefore be built into the order process. The laboratory should define when:

• A pathology review is required before submission.
• A block or slide must be selected by an authorized reviewer.
• Additional tissue should be reserved for ancillary studies.
• A specimen is unsuitable for the requested panel.
• The ordering team should consider an alternative specimen.
• A repeat collection is likely to be required.

This protects both margin and patient experience. A test that cannot generate a reliable result should not enter the high-cost workflow simply because the order exists.

Separate analytical validation from utilization policy

A validated assay is not automatically an appropriate assay for every patient. Analytical validation establishes what the test can measure under defined conditions. Utilization governance determines when the test should be ordered, how it fits the diagnostic pathway, and what evidence supports its use.

The two functions should remain connected but distinct. Pathology and laboratory medicine leaders must protect analytical integrity. Utilization committees must manage clinical indications, sequencing, payer requirements, and resource allocation.

This separation is especially important when new panels are introduced. Commercial availability can move faster than internal governance. Before launch, the organization should document:

• Intended use.
• Specimen requirements.
• Expected turnaround time.
• Confirmatory testing requirements.
• Result interpretation and reporting ownership.
• Payer and prior-authorization workflow.
• Referral or send-out dependencies.
• Escalation route for uncertain findings.
• Sunset or review date for the utilization policy.

Link panel ordering to reimbursement and revenue cycle

High-cost genomic testing creates exposure across the revenue cycle. A laboratory may improve technical throughput while worsening financial performance if claims are denied, authorization is incomplete, or documentation does not support medical necessity.

The utilization workflow should connect the order to:

• Coverage criteria.
• Prior authorization status.
• Required clinical documentation.
• Correct patient and specimen identifiers.
• Billing and coding review.
• Financial responsibility communication where applicable.
• Denial reason analysis.

Payer coverage is not universal, and no genomic panel should be treated as automatically reimbursable. At the same time, the laboratory should not assume that a high price makes a test clinically or financially indefensible. The correct approach is controlled verification before the test consumes scarce capacity.

In precision medicine, the most expensive failure is often not the assay price. It is generating a technically valid result that cannot be interpreted, reimbursed, or used to make a timely decision.

A practical governance model can be summarized as follows:

Reference pricing and payer-driven controls

Reference pricing is one of the clearest examples of a financial control that can alter laboratory utilization without relying solely on physician behavior. A reported implementation reduced clinical laboratory test prices by 17.8% in the first year and by 27.7% by the third year.

The mechanism is straightforward. A defined payment reference point changes the financial consequence of selecting higher-priced laboratories or tests when lower-cost alternatives are available. But price controls are not a substitute for clinical governance. They must be designed so that the lower-cost option meets the required standards for quality, turnaround, specimen handling, and result interpretation.

The laboratory should treat reference pricing as part of a broader supply chain and payer strategy. Before changing preferred pathways, leadership should examine:

• Analytical equivalence or clinically acceptable performance.
• Accreditation and quality requirements.
• Turnaround time for urgent and routine testing.
• Specimen transport conditions.
• Chain of custody for referred specimens.
• Result integration into the LIS and EHR.
• Availability of pathologist or laboratory medicine consultation.
• Denial and appeal patterns.
• Impact on internal throughput and staffing.

A lower unit price can produce a higher total cost if it creates manual reconciliation, delayed results, duplicate testing, or increased specimen rejection. The relevant metric is total cost to diagnose, not the price printed beside a single assay.

Use formulary management with clinical exceptions

A laboratory test formulary should identify preferred tests, restricted tests, send-out tests, and tests that require specialist review. It should also define acceptable exceptions.

The formulary works best when it is treated like a medication formulary with laboratory-specific logic:

• Preferred test for a routine indication.
• Alternative test where the preferred option is unavailable or unsuitable.
• Restricted test for defined clinical indications.
• Reflex pathway to prevent unnecessary escalation.
• Review requirement for high-cost or high-complexity orders.
• Periodic reassessment based on utilization, performance, reimbursement, and clinical outcomes.

A rigid formulary will fail when it ignores actual clinical practice. A permissive formulary will fail when it contains no prioritization. The management task is to make the appropriate pathway visible, defensible, and operationally faster than an exception.

Protect compliance while reducing administrative friction

Utilization management must align with CLIA requirements, CAP accreditation expectations, local policies, and the organization’s documented quality system. The compliance risk is not limited to performing an unauthorized test. It also includes:

• Inconsistent application of restrictions.
• Missing documentation for exceptions.
• Uncontrolled changes to reflex rules.
• Inadequate validation of modified workflows.
• Ambiguous responsibility for result review.
• Incomplete specimen traceability.
• Failure to monitor the effect of a new policy.

The 2017 CLSI GP49 guideline release reinforced the need for structured medical laboratory management. Governance should reflect that principle. Changes to test access, ordering logic, reflex pathways, or send-out arrangements require documented ownership, review, implementation control, and monitoring.

The compliance file should make it possible to answer a simple question: who approved this workflow, on what basis, and how does the organization know it continues to perform as intended?

A management framework for laboratory utilization

The most reliable programs move through a defined sequence. Not every laboratory needs a large committee or a new technology platform. Every laboratory does need disciplined prioritization.

1. Establish a baseline

Start with the tests that create the largest combination of volume, cost, repeat activity, or clinical uncertainty. Do not begin with an abstract target to reduce total orders. Identify the actual failure points.

The baseline should include:

• Current order volume.
• Repeat-order intervals.
• Unit and total cost.
• Send-out exposure.
• Specimen rejection rate.
• Turnaround time.
• Cancellation and modification rates.
• Payer denials.
• Override frequency.
• Result follow-up failures.

2. Select high-value interventions

Choose interventions that match the failure. Use a duplicate alert for duplicate ordering. Use a reflex rule for predictable sequencing. Use specimen triage for material limitations. Use payer review for authorization risk. Do not impose manual review where a reliable electronic control can perform the work.

3. Pilot before scaling

A limited pilot provides operational evidence. It shows whether the alert is too broad, whether clinicians understand the language, whether the review queue is manageable, and whether the intervention shifts orders into an unintended pathway.

The pilot should measure more than avoided tests. Track turnaround time, override reasons, rejected specimens, downstream testing, and clinician escalation.

4. Report clinical and financial outcomes together

A cost-only report invites skepticism and encourages unsafe reductions. A clinically focused report that ignores margin will not survive executive review. The dashboard must show both.

Useful categories include:

• Utilization volume.
• Avoided duplicate testing.
• Appropriate reflex completion.
• Cost per completed diagnostic episode.
• High-cost panel yield.
• Denial rate.
• Specimen failure.
• Turnaround time.
• Abnormal-result follow-up.
• Underutilization indicators.
• Compliance exceptions.

5. Retire controls that no longer work

A rule is not valuable because it exists. It is valuable because it changes behavior or prevents failure without imposing greater risk elsewhere. Alerts with high override rates, low clinical relevance, or excessive administrative cost should be revised or removed.

The same applies to formularies. A test restriction that no longer reflects payer coverage, assay availability, or clinical practice is an operational liability.

The laboratory director’s mandate

Laboratory diagnostic test utilization management strategies work when they are built as operating infrastructure. They fail when they are presented as a one-time campaign against unnecessary orders.

The economic signal is already clear. Approximately one in five laboratory orders may be overutilized on average across reviewed settings. In a large claims analysis, nearly one quarter of tested individuals experienced excessive testing across selected outpatient categories. Precision medicine raises the stakes further, with genomic panels reaching five-figure prices. Reference pricing can materially reduce laboratory prices, but only when it is integrated with quality, access, and workflow controls.

The appropriate response is not indiscriminate restriction. It is disciplined design:

• Put clinical logic inside the ordering workflow.
• Use reflex algorithms where sequencing is predictable.
• Measure repeat testing and omitted testing together.
• Protect specimen quality before expensive analysis begins.
• Connect LIS, EHR, payer, and revenue cycle data.
• Assign ownership for every exception and every abnormal result.
• Review high-cost molecular testing as a service line.
• Treat compliance as a workflow property, not a final audit step.

Hospitals and reference laboratories that ignore utilization will continue to absorb avoidable cost through volume, rework, denials, and capacity loss. Those that respond with blunt cuts will create diagnostic risk. The sustainable position is narrower and more demanding: every test must earn its place in the pathway, and the organization must be able to show why it belongs there.